A recent study published in the European Journal of Neuroscience provides new insights into how 3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy or molly, affects the brain’s processing of emotional stimuli. Researchers found that MDMA significantly altered the brain’s response to emotional faces, shedding light on the drug’s unique impact on social and emotional processing.
MDMA is known for its recreational use due to its euphoric and empathogenic effects. It is also under investigation as a potential treatment for post-traumatic stress disorder (PTSD) when combined with psychotherapy. Despite its widespread use and therapeutic potential, the specific neural and behavioral effects of MDMA are not fully understood.
The researchers designed a double-blind study to investigate how MDMA and methamphetamine affect the brain’s response to emotional stimuli. The study involved 25 healthy adults, aged 18 to 35, who had previously used MDMA.
The participants attended three separate sessions, each spaced at least four days apart, where they received either MDMA (100 mg), methamphetamine (20 mg), or a placebo in random order. This approach ensured that neither the participants nor the researchers knew which substance was administered at each session, minimizing bias.
Before each session, participants were screened for recent drug or alcohol use, and women were tested for pregnancy. During each session, the participants took the assigned substance and, after allowing time for the drug to take effect, they were fitted with electroencephalography (EEG) electrodes to measure brain activity.
The participants then engaged in an emotional oddball task, which involved identifying human faces showing different emotions (happy, angry, neutral) interspersed with frequent cartoon faces. The EEG recorded the participants’ brain responses to these stimuli, focusing on specific event-related potentials (ERPs), which are brain responses to specific sensory, cognitive, or motor events.
The researchers found that both MDMA and methamphetamine increased participants’ subjective feelings of the drug’s effects. Participants reported higher levels of feeling the drug, liking its effects, and wanting more of the drug when they took MDMA or methamphetamine compared to the placebo. Notably, MDMA also increased feelings of friendliness, aligning with its reputation for enhancing social and emotional experiences.
In terms of brain activity, MDMA had a unique effect on the N170 ERP component, which is associated with the early processing of facial features. The N170 amplitude increased significantly in response to happy and angry faces when participants took MDMA, but not in response to neutral faces. This suggests that MDMA specifically enhances the brain’s response to emotionally salient stimuli. In contrast, methamphetamine did not affect the N170 amplitude, indicating that MDMA has a distinct impact on emotional face processing that is not shared by other stimulants.
The researchers also examined the P300 and mismatch negativity (MMN) components, which are related to attention allocation and responses to novel stimuli, respectively. Neither MDMA nor methamphetamine significantly affected these ERP components. This finding indicates that MDMA’s influence is more specific to the early visual processing of emotional stimuli rather than broader cognitive or novelty responses.
“The present findings have implications for MDMA-assisted therapy,” the researchers explained. “The increased neural response to the sensory component of viewing faces could contribute to the therapeutic alliance between patients and their therapists. By increasing attention to facial emotional cues, the drug may increase interpersonal connection in the therapeutic environment.
“MDMA may also facilitate the identification and processing of emotions, allowing patients to build trust, and engage more deeply with their emotional experiences. Further studies of this kind are needed to understand the brain mechanisms underlying the behavioural effects of MDMA and other pro-social drugs.”
The study highlights MDMA’s unique ability to enhance the brain’s early processing of emotional stimuli, distinguishing it from other stimulants like methamphetamine. But there are some caveats. The sample was homogeneous, consisting of healthy young adults with prior MDMA use, which may not generalize to other populations.
Future research should include more diverse populations, varied doses, and extended washout periods. Additionally, using more complex social and emotional tasks could provide a deeper understanding of MDMA’s effects on social behavior and cognition. Investigating long-term users of MDMA and comparing their neural responses to those of non-users could also yield valuable insights.
The study, “The 3,4-methylenedioxymethamphetamine enhances early visual processing for salient socio-emotional stimuli,” was authored by Connor J. Haggarty, Anya K. Bershad, Mahesh K. Kumar, Royce Lee, and Harriet de Wit.
